Codon 215 mutations in combination with M41L in reverse transcriptase (RT) confer high-level zidovudine (AZT) resistance on human immunodeficiency virus (HIV) (9, 11) . M184V gives resistance to lamivudine (3TC) (20, 23) and restores AZT sensitivity to codon 41 and 215 mutations (12) . X-ray crystallographic results indicate that residues 41 and 215 in HIV-1 RT are distal to the deoxynucleoside triphosphate binding site (6, 7, 10, 16) , and ideas as to how AZT resistance is induced include template rearrangement (3) and conformational changes propagated from residues 215 and 219 for the mutant RTMC (D67N, K70R, T215F, and K219N) (17) . Biochemical studies have shown a mechanism of AZT resistance involving AZTMP removal from the blocked primer strand in a pyrophosphate-or ATP-dependent pyrophosphorolysis reaction enhanced by RTMC and other mutant RTs (1, 2, 13, 14) . Model building studies suggest that T215Y might promote ATP binding, the presumed physiological acceptor for the pyrophosphorolysis reaction (2) . To investigate further the effects of AZT and 3TC drug resistance mutations on the conformational states of HIV-1 RT, structures of a series of six AZT-and/or 3TC-resistant RTs mainly containing combinations of M41L, T215Y, and M184V mutations were determined in the absence of oligonucleotide or deoxynucleoside triphosphate substrates to assess whether underlying baseline structural rearrangements are induced by these mutations in a way analogous to that previously observed for RTMC.
Site-directed mutants were introduced into the HIV-1 HXB2-D RT coding region by using ExSite or QuikChange kits (Stratagene). Expression, purification, and crystallization of RT (as complexes with nevirapine or the nevirapine analogue 1051U91) were performed as described previously (5, 22, 24) . Six RT mutants were purified and crystallized, and structures were determined for five of these (Table 1) , whereas the sixth mutant, RTϩM41L, gave disordered crystals unsuitable for data collection. X-ray data were collected at synchrotron sources (Table 1) , and DENZO and SCALEPACK were used for data processing (15) . The orientation and translation of HIV-1 RT in the unit cell were determined by using rigid-body refinement with XPLOR, and refinement was done with XPLOR or CNS (4) as described previously (18) . For data sets too small for full refinement, tight positional restraints were applied. Table 1 gives statistics on X-ray data quality and refinement statistics. Coordinates and structure factors have been deposited in the Protein Data Bank (PDB) for immediate release (see Table 1 for PDB codes). O (8) was used for mutating side chains in the RT-DNA complex (PDB code 1rtd) (6) and docking in ATP.
Omit maps show electron density for the mutated side chains in p66 (Fig. 1) . Y215 is clearly defined (Fig. 1b, d , g, and h), while for L41 the density is less clear within p66 (Fig. 1c and e) than in p51; nevertheless, its conformation could be determined. In the RTMQϩM184V structure the 67 and 70 side chains are disordered.
Electron density for the M184V mutation is clear in all cases ( Fig. 1a and f) compared to the previously reported RTϩM184I structure which had the mutated residue disordered in the unliganded structure but defined in the binary complex with DNA (19) .
Comparison of the structures of this present set of mutant RTs with wild-type RT-nevirapine complexes shows only minor conformational changes in the protein (Fig. 2a) . Structural differences at the ␤9-␤10 loop region appear related to the various crystal forms, and such effects can be separated from differences in inhibitor binding or drug resistance mutations. These results are distinct from the previously determined structure of an AZT-resistant RT containing a different set of mutations (RTMC: D67N, K70R, T215F, and K219N), where significant movement of the polymerase active site and the Y181 side chain is observed (17) . The RTMF-1051U91 structure is essentially identical to that with nevirapine, indicating that the conformational variation compared to RTMC could not be ascribed to these different inhibitors (Fig. 2b) . There are differences between the particular AZT resistance mutations for RTMC and those for RTMF or RTMN. RTMC has, in addition to the change at codon 215, mutations at 67, 70, and 219, and none of the latter are present in RTMF or RTMN. It was determined from the earlier structural studies that the observed conformational changes that propagated toward the active site and the nonnucleoside RT inhibitor (NNRTI)-binding site apparently originated from residues 215 and 219 (17) , and it is possible that the 219 mutation in combination with T215F (in place of T215Y in RTMN) could give rise to the conformational rearrangement in the RTMC active and NNRTI sites. RTMN is from a mutant virus that shows highlevel AZT resistance, and yet the polymerase active site has essentially the same conformation as does wild-type RT, hence indicating a lack of correlation between resistance phenotype and the active site conformational state of substratefree RT. RTs containing the M184V mutation either in the absence or in the presence of AZT resistance mutations have similar conformational states. The reversal effect of M184V on AZT resistance may in any case be mediated by more direct effects, since residue 184 is positioned close to the termination site on the blocked primer. However, drug resistance mutation-dependent conformational changes might occur in higher-order complexes involving bound substrates or other ligands.
The side chain conformations of the mutated 41 and 215 residues from the structures determined here were modeled into the ternary complex of RT-template-primer-dTTP (6) followed by the docking of ATP, based on the mode predicted from the nature of the pyrophosphorolysis reaction (2, 21) . This showed that ATP cannot simultaneously contact the mutated side chains of residues 215 and 41 (Fig. 3) . Contacts with the Y215 side chain could be made via parallel aromatic ring stacking of the adenine base of ATP, forming a number of van der Waals contacts as has been noted previously (2, 21) . Structural mechanisms whereby the mutation of M41L could lead to increased ATP binding are less clear. M41 is located some distance from Y215 and is somewhat buried, making direct interaction with ATP unlikely. The M41L mutation introduces a branched side chain that potentially might disrupt this buried region; however, structures of RTMN and RTMNϩM184V reveal that this change is accommodated without significant rearrangement of the protein. It thus seems more likely that a conformational rearrangement occurs either within the catalytic complex or on binding of ATP rather than that there are two distinct ATP binding positions, each of which is strengthened by the mutations at either residue 41 or residue 215. The former model would be consistent with the synergistic effect of the combination of M41L and T215Y on AZT drug resistance. The putative further conformational change could lead to an indirect effect on ATP binding via intervening side chains, such as that formed by contact between residues 116 and 41, or main chain elements rather than repositioning the mutated 41 and 215 side chains to simultaneously interact with ATP. Further work is required to test such possibilities, in particular determination of a range of HIV-1 RT mutant-DNA structures including complexes with ATP.
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